Dr Frank van Leth

All Stories

1. 
   Correction to Diagnostic accuracy and predictive value of the QuantiFERON-TB gold plus assay for tuberculosis in immunocompromised individuals: a prospective TBnet study Lancet Reg Health Eur 57 (2025) 101416 LLRHEUROPE-D-25-00310

   Article • The Lancet Regional Health - Europe, December 2025, Elsevier

   Dr Frank van Leth

2. 
   Diagnostic accuracy and predictive value of the QuantiFERON-TB gold plus assay for tuberculosis in immunocompromised individuals: a prospective TBnet study

   Article • The Lancet Regional Health - Europe, October 2025, Elsevier

   Dr Frank van Leth

3. 
   Syndemic processes between non-communicable diseases and HIV within the Kingdom of Eswatini

   Article • Journal of Epidemiology & Community Health, July 2025, BMJ

   Dr Frank van Leth

4. 
   Statistical Methods to Adjust for Treatment Switching in Real‐World Clinical Studies: A Scoping Review and Descriptive Comparison

   Article • Clinical Pharmacology & Therapeutics, July 2025, Wiley

   Dr Frank van Leth

5. 
   Assessing the quality of amoxicillin in the private market in Indonesia: a cross-sectional survey exploring product variety, market volume and price factors

   Article • BMJ Open, July 2025, BMJ

   Dr Frank van Leth

6. 
   Neighbourhood factors and tuberculosis incidence in Cape Town: A negative binomial regression and spatial analysis

   Article • Tropical Medicine & International Health, May 2024, Wiley

   Dr Frank van Leth

7. 
   The plasma kynurenine-to-tryptophan ratio as a biomarker of tuberculosis disease in people living with HIV on antiretroviral therapy: an exploratory nested case–control study

   Article • BMC Infectious Diseases, April 2024, Springer Science + Business Media

   Dr Frank van Leth

8. 
   The clinical usefulness of guideline-based strategies with and without the role of nonspecific symptoms to predict urinary tract infections in nursing homes: a decision curve analysis

   Article • Antimicrobial Stewardship & Healthcare Epidemiology, January 2024, Cambridge University Press

   Dr Frank van Leth

9. 
   Estimating the contribution of subclinical tuberculosis disease to transmission: An individual patient data analysis from prevalence surveys

   Article • eLife, December 2023, eLife

   Dr Frank van Leth

10. 
    Reasons for using traditional and complementary care by people living with HIV on antiretroviral therapy and association with interrupted care: a mixed methods study in Eswatini

    Article • BMC Complementary Medicine and Therapies, October 2023, Springer Science + Business Media

    Dr Frank van Leth

11. 
    Monocyte to lymphocyte ratio and hemoglobin level to predict tuberculosis after antiretroviral therapy initiation

    Article • AIDS, September 2023, Wolters Kluwer Health

    Dr Frank van Leth

12. 
    Relative cost of multidrug-resistant TB medicines in Europe

    Article • The International Journal of Tuberculosis and Lung Disease, May 2023, International Union Against Tuberculosis and Lung Disease

    Dr Frank van Leth

13. 
    Clinical implications of molecular drug resistance testing for Mycobacterium tuberculosis: a 2023 TBnet/RESIST-TB consensus statement

    Article • The Lancet Infectious Diseases, April 2023, Elsevier

    Paolo Miotto, Dr Frank van Leth

14. 
    Unbiased antimicrobial resistance prevalence estimates through population-based surveillance

    Article • Clinical Microbiology and Infection, April 2023, Elsevier

    Dr Frank van Leth

15. 
    Strengthening primary care for diabetes and hypertension in Eswatini: study protocol for a nationwide cluster-randomized controlled trial

    Article • Trials, March 2023, Springer Science + Business Media

    Dr Frank van Leth

16. 
    Predictive performance of interferon-gamma release assays and the tuberculin skin test for incident tuberculosis: an individual participant data meta-analysis

    Article • EClinicalMedicine, February 2023, Elsevier

    Dr Frank van Leth

17. 
    Availability and costs of medicines for the treatment of tuberculosis in Europe

    Article • Clinical Microbiology and Infection, January 2023, Elsevier

    Dr Frank van Leth

18. 
    Reasons for, and factors associated with, positive HIV retesting: a cross-sectional study in Eswatini

    Article • AIDS Care, November 2022, Taylor & Francis

    Dr Frank van Leth

19. 
    Neighbourhood risk factors of recurrent tuberculosis in Cape Town: a cohort study using geocoded notification data

    Article • Journal of Epidemiology & Community Health, November 2022, BMJ

    Dr Frank van Leth

20. 
    Does distance to healthcare facility affect care-seeking for TB-related symptoms in Tanzania?

    Article • The International Journal of Tuberculosis and Lung Disease, August 2022, International Union Against Tuberculosis and Lung Disease

    Dr Frank van Leth

21. 
    Estimating the contribution of subclinical tuberculosis disease to transmission – an individual patient data analysis from prevalence surveys

    Article • June 2022, Cold Spring Harbor Laboratory Press

    Dr Frank van Leth

22. 
    Rifapentine access in Europe: growing concerns over key tuberculosis treatment component

    Article • European Respiratory Journal, May 2022, European Respiratory Society (ERS)

    Dr Frank van Leth

23. 
    Clinical Reasoning Underlying Guideline Nonadherence in Urinary Tract Infections in Nursing Homes

    Article • Journal of the American Medical Directors Association, May 2022, Elsevier

    Dr Frank van Leth

24. 
    Incidence and factors associated with active tuberculosis among people living with HIV after long-term antiretroviral therapy in Thailand: a competing risk model

    Article • BMC Infectious Diseases, April 2022, Springer Science + Business Media

    Dr Frank van Leth

25. 
    Monocyte-to-lymphocyte ratio as a predictor of TB among people living with HIV

    Article • The International Journal of Tuberculosis and Lung Disease, November 2021, International Union Against Tuberculosis and Lung Disease

    Dr Frank van Leth

26. 
    Diapers as Promising Alternative Collection Method for Urine Specimens in Nursing Home Residents: A Noninferiority Study

    Article • Journal of the American Medical Directors Association, June 2021, Elsevier

    Dr Frank van Leth

27. 
    Prediction of anti-tuberculosis treatment duration based on a 22-gene transcriptomic model

    Article • European Respiratory Journal, February 2021, European Respiratory Society (ERS)

    Jan Heyckendorf, Prof. Dr. Torsten Goldmann, Dr Frank van Leth

28. 
    Use and impact of molecular methods for detecting drug‐resistant TB

    Article • The International Journal of Tuberculosis and Lung Disease, February 2021, International Union Against Tuberculosis and Lung Disease

    Dr Frank van Leth

29. 
    Antimicrobial resistance among uropathogens in the Asia-Pacific region: a systematic review

    Article • JAC-Antimicrobial Resistance, January 2021, Oxford University Press (OUP)

    Dr Frank van Leth

30. 
    Defining Outcomes of Tuberculosis (Treatment): From the Past to the Future

    Article • Respiration, January 2021, Karger Publishers

    Dr Frank van Leth

31. 
    Sensitivity of C-Reactive Protein and Procalcitonin Measured by Point-of-Care Tests to Diagnose Urinary Tract Infections in Nursing Home Residents: A Cross-Sectional Study

    Article • Clinical Infectious Diseases, November 2020, Oxford University Press (OUP)

    Dr Frank van Leth

32. 
    “A false sense of confidence” The perceived role of inflammatory point-of-care testing in managing urinary tract infections in Dutch nursing homes: a qualitative study

    Article • BMC Geriatrics, November 2020, Springer Science + Business Media

    Dr Frank van Leth

33. 
    Appropriateness of diagnosis and antibiotic use in sepsis patients admitted to a tertiary hospital in Indonesia

    Article • Postgraduate Medicine, October 2020, Taylor & Francis

    Dr Frank van Leth

34. 
    Discovery and validation of a personalized risk predictor for incident tuberculosis in low transmission settings

    Article • Nature Medicine, October 2020, Springer Science + Business Media

    Dr Frank van Leth

35. 
    Laboratory-based versus population-based surveillance of antimicrobial resistance to inform empirical treatment for suspected urinary tract infection in Indonesia

    Article • PLOS One, March 2020, PLOS

    Dr Frank van Leth

36. 
    Mass drug administrations with dihydroartemisinin-piperaquine and single low dose primaquine to eliminate Plasmodium falciparum have only a transient impact on Plasmodium vivax: Findings from randomised controlled trials

    Article • PLOS One, February 2020, PLOS

    Dr Frank van Leth

37. 
    The use of ultrasensitive quantitative-PCR to assess the impact of primaquine on asymptomatic relapse of Plasmodium vivax infections: a randomized, controlled trial in Lao PDR

    Article • Malaria Journal, January 2020, Springer Science + Business Media

    Dr Frank van Leth

38. 
    Bridging the TB data gap: in silico extraction of rifampicin-resistant tuberculosis diagnostic test results from whole genome sequence data

    Article • PeerJ, August 2019, PeerJ

    Dr Frank van Leth

39. 
    Sensitivity of point-of-care testing C reactive protein and procalcitonin to diagnose urinary tract infections in Dutch nursing homes: PROGRESS study protocol

    Article • BMJ Open, August 2019, BMJ

    Dr Frank van Leth

40. 
    Management of patients with multidrug-resistant tuberculosis

    Article • The International Journal of Tuberculosis and Lung Disease, June 2019, International Union Against Tuberculosis and Lung Disease

    Dr Frank van Leth

41. 
    Changes in disclosure, adherence and healthcare interactions after the introduction of immediate ART initiation: an analysis of patient experiences in Swaziland

    Article • Tropical Medicine & International Health, March 2019, Wiley

    Dr Frank van Leth

42. 
    Rethinking Antimicrobial Resistance Surveillance: A Role for Lot Quality Assurance Sampling

    Article • American Journal of Epidemiology, January 2019, Oxford University Press (OUP)

    Dr Frank van Leth, R. Lia Kusumawati

43. 
    The Tuberculosis Network European Trials group (TBnet) ERS Clinical Research Collaboration: addressing drug-resistant tuberculosis through European cooperation

    Article • European Respiratory Journal, January 2019, European Respiratory Society (ERS)

    Dr Frank van Leth

44. 
    Pharmacy-based hypertension care employing mHealth in Lagos, Nigeria – a mixed methods feasibility study

    Article • BMC Health Services Research, December 2018, Springer Science + Business Media

    Dr Frank van Leth

45. 
    Clinical Management of Multidrug-Resistant Tuberculosis in 16 European Countries

    Article • American Journal of Respiratory and Critical Care Medicine, August 2018, American Thoracic Society

    Dr Frank van Leth, Dr Valeriu Crudu

46. 
    Predictive value of the urinary dipstick test in the management of patients with urinary tract infection-associated symptoms in primary care in Indonesia: a cross-sectional study

    Article • BMJ Open, August 2018, BMJ

    Dr Frank van Leth, R. Lia Kusumawati

47. 
    Testing for LTBI: more of the same or a step forward?

    Article • The International Journal of Tuberculosis and Lung Disease, June 2018, International Union Against Tuberculosis and Lung Disease

    Dr Frank van Leth

48. 
    Time to revise WHO-recommended definitions of MDR-TB treatment outcomes

    Article • The Lancet Respiratory Medicine, April 2018, Elsevier

    Dr Frank van Leth

49. 
    Treatment responses in multidrug-resistant tuberculosis in Germany

    Article • The International Journal of Tuberculosis and Lung Disease, April 2018, International Union Against Tuberculosis and Lung Disease

    Dr Frank van Leth

50. 
    Relapse-free cure from multidrug-resistant tuberculosis in Germany

    Article • European Respiratory Journal, February 2018, European Respiratory Society (ERS)

    Dr Frank van Leth

51. 
    Reply: Benefit of the Shorter Multidrug-Resistant Tuberculosis Treatment Regimen in California and Modified Eligibility Criteria

    Article • American Journal of Respiratory and Critical Care Medicine, December 2017, American Thoracic Society

    Dr Frank van Leth, Professor JEROME ROBERT, Dr Valeriu Crudu

52. 
    Tuberculosis Treatment Outcomes in Europe: Based on Treatment Completion, Not Cure

    Article • American Journal of Respiratory and Critical Care Medicine, November 2017, American Thoracic Society

    Dr Frank van Leth, Dr Valeriu Crudu

53. 
    Treatment outcomes of MDR-TB and HIV co-infection in Europe

    Article • European Respiratory Journal, June 2017, European Respiratory Society (ERS)

    Dr Valeriu Crudu, Dr Frank van Leth

54. 
    An easy tool to assess ventilation in health facilities as part of air-borne transmission prevention: a cross-sectional survey from Uganda

    Article • BMC Infectious Diseases, May 2017, Springer Science + Business Media

    Dr Frank van Leth

55. 
    Tuberculosis resistance-conferring mutations with fitness cost among HIV-positive individuals in Uganda

    Article • The International Journal of Tuberculosis and Lung Disease, May 2017, International Union Against Tuberculosis and Lung Disease

    Dr Frank van Leth, Willy SSENGOOBA

56. 
    A rapid method to assess the prevalence of antimicrobial resistance

    Article • Future Microbiology, April 2017, Future Medicine

    Dr Frank van Leth

57. 
    Antimicrobial resistance in uropathogens and appropriateness of empirical treatment: a population-based surveillance study in Indonesia

    Article • Journal of Antimicrobial Chemotherapy, January 2017, Oxford University Press (OUP)

    Dr Frank van Leth, R. Lia Kusumawati

58. 
    More on Treatment Outcomes in Multidrug-Resistant Tuberculosis

    Article • The New England Journal of Medicine and Surgery and the Collateral Branches of Science, December 2016, New England Journal of Medicine (NEJM/MMS)

    Dr Frank van Leth

59. 
    Prevention of Early Mortality by Presumptive Tuberculosis Therapy Study: An Open Label, Randomized Controlled Trial

    Article • American Journal of Tropical Medicine and Hygiene, December 2016, American Society of Tropical Medicine and Hygiene

    Dr Frank van Leth, Prof Robert Colebunders

60. 
    Effect of secondary preventive therapy on recurrence of tuberculosis in HIV-infected individuals: a systematic review

    Article • Infectious Diseases, December 2016, Taylor & Francis

    Dr Frank van Leth

61. 
    Limited Benefit of the New Shorter Multidrug-Resistant Tuberculosis Regimen in Europe

    Article • American Journal of Respiratory and Critical Care Medicine, October 2016, American Thoracic Society

    Dr Frank van Leth, Professor JEROME ROBERT, Dr Valeriu Crudu

62. 
    Population impact of factors associated with prevalent pulmonary tuberculosis in Tanzania

    Article • The International Journal of Tuberculosis and Lung Disease, October 2016, International Union Against Tuberculosis and Lung Disease

    Dr Frank van Leth

63. 
    Urgent need to rethink treatment outcome definitions in tuberculosis

    Article • The New England Journal of Medicine and Surgery and the Collateral Branches of Science, September 2016, New England Journal of Medicine (NEJM/MMS)

    Dr Frank van Leth, Dr Valeriu Crudu

64. 
    Intention of physicians to implement guidelines for screening and treatment of latent tuberculosis infection in HIV-infected patients in The Netherlands: a mixed-method design

    Article • BMC Public Health, September 2016, Springer Science + Business Media

    Dr Frank van Leth

65. 
    Prevalence of pulmonary tuberculosis in adult population of Tanzania: a national survey, 2012

    Article • The International Journal of Tuberculosis and Lung Disease, August 2016, International Union Against Tuberculosis and Lung Disease

    Dr Frank van Leth

66. 
    Viral Load and Risk of Tuberculosis in HIV Infection

    Article • JAIDS Journal of Acquired Immune Deficiency Syndromes, February 2016, Wolters Kluwer Health

    Dr Frank van Leth, Dirk Wagner

67. 
    TB-HIV co-infection in the Netherlands: estimating prevalence and under-reporting in national registration databases using a capture–recapture analysis

    Article • Journal of Epidemiology & Community Health, December 2015, BMJ

    Dr Frank van Leth

68. 
    Beyond multidrug-resistant tuberculosis in Europe: a TBNET study

    Article • The International Journal of Tuberculosis and Lung Disease, December 2015, International Union Against Tuberculosis and Lung Disease

    Dr Frank van Leth, Dr Valeriu Crudu

69. 
    Numbers needed to treat to prevent tuberculosis: TABLE 1

    Article • European Respiratory Journal, November 2015, European Respiratory Society (ERS)

    Professor Martina Sester, Dr Frank van Leth

70. 
    Health care-seeking behaviour among people with cough in Tanzania: findings from a tuberculosis prevalence survey

    Article • The International Journal of Tuberculosis and Lung Disease, June 2015, International Union Against Tuberculosis and Lung Disease

    Dr Frank van Leth

71. 
    Latent tuberculosis infection as a target for tuberculosis control

    Article • Future Microbiology, June 2015, Future Medicine

    Dr Frank van Leth

72. 
    Factors associated with poor knowledge among adults on tuberculosis in Bangladesh: results from a nationwide survey

    Article • Journal of Health Population and Nutrition, May 2015, Springer Science + Business Media

    Dr Frank van Leth

73. 
    Multidrug-Resistant Tuberculosis in Europe, 2010–2011

    Article • Emerging Infectious Diseases, March 2015, Centers for Disease Control and Prevention (CDC)

    Dr Valeriu Crudu, Dr Valeriu Crudu, Dr Simon Tiberi, Dr Emanuele Pontali, Dr Frank van Leth

74. 
    Implementation of tuberculosis infection prevention and control in Mozambican health care facilities

    Article • The International Journal of Tuberculosis and Lung Disease, January 2015, International Union Against Tuberculosis and Lung Disease

    Dr Frank van Leth

75. 
    Healthcare Workers' Challenges in the Implementation of Tuberculosis Infection Prevention and Control Measures in Mozambique

    Article • PLOS One, December 2014, PLOS

    Dr Frank van Leth

76. 
    Risk Assessment of Tuberculosis in Immunocompromised Patients. A TBNET Study

    Article • American Journal of Respiratory and Critical Care Medicine, November 2014, American Thoracic Society

    Dr Frank van Leth, Dirk Wagner

77. 
    Availability, price and affordability of anti-tuberculosis drugs in Europe: a TBNET survey

    Article • European Respiratory Journal, November 2014, European Respiratory Society (ERS)

    Dr Frank van Leth

78. 
    Validation of indirect tuberculosis treatment adherence measures in a resource-constrained setting

    Article • The International Journal of Tuberculosis and Lung Disease, July 2014, International Union Against Tuberculosis and Lung Disease

    Dr Frank van Leth

79. 
    Antimicrobial drug resistance among clinically relevant bacterial isolates in sub-Saharan Africa: a systematic review

    Article • Journal of Antimicrobial Chemotherapy, May 2014, Oxford University Press (OUP)

    Dr Frank van Leth

80. 
    Care seeking in tuberculosis: results from a countrywide cluster randomised survey in Bangladesh

    Article • BMJ Open, May 2014, BMJ

    Dr Frank van Leth

81. 
    Embracing the challenges of HIV-TB co-infection in children [Editorial]

    Article • The International Journal of Tuberculosis and Lung Disease, April 2014, International Union Against Tuberculosis and Lung Disease

    Dr Frank van Leth

82. 
    Management of patients with multidrug-resistant/extensively drug-resistant tuberculosis in Europe: a TBNET consensus statement

    Article • European Respiratory Journal, March 2014, European Respiratory Society (ERS)

    Dr Valeriu Crudu, Dr Valeriu Crudu, Dr Frank van Leth, Dr Enrico Tortoli, Dirk Wagner

83. 
    Antiretroviral therapy and tuberculosis: does the regimen matter?

    Article • Expert Review of Anti-infective Therapy, January 2014, Taylor & Francis

    Dr Frank van Leth

84. 
    Polio and the risk for the European Union

    Article • The Lancet, January 2014, Elsevier

    Dr Frank van Leth

85. 
    Design of pragmatic trials of tuberculosis interventions

    Article • The Lancet, January 2014, Elsevier

    Dr Frank van Leth

86. 
    Epidemiology of Tuberculosis in an Urban Slum of Dhaka City, Bangladesh

    Article • PLOS One, October 2013, PLOS

    Dr Frank van Leth

87. 
    TB diagnostic process management of patients in a referral hospital in Mozambique in comparison with the 2007 WHO recommendations for the diagnosis of smear-negative pulmonary TB and extrapulmonary TB

    Article • International Health, October 2013, Oxford University Press (OUP)

    Dr Frank van Leth

88. 
    Tuberculin survey in Bangladesh, 2007–2009: prevalence of tuberculous infection and implications for TB control

    Article • The International Journal of Tuberculosis and Lung Disease, October 2013, International Union Against Tuberculosis and Lung Disease

    Dr Frank van Leth

89. 
    Epidemiological Surveys Embedded in Technical Assistance to Tuberculosis Control Programmes

    Article • The Open Infectious Diseases Journal, April 2013, Bentham Science Publishers

    Dr Frank van Leth

90. 
    Editorial - Technical Assistance to Tuberculosis Control Programmes as a Platform for Infectious Disease Research

    Article • The Open Infectious Diseases Journal, April 2013, Bentham Science Publishers

    Dr Frank van Leth

91. 
    Predictive Value of the Tuberculin Skin Test among Newly Arriving Immigrants

    Article • PLOS One, March 2013, PLOS

    Dr Frank van Leth

92. 
    Health workers’ performance in the implementation of Patient Centred Tuberculosis Treatment (PCT) strategy under programmatic conditions in Tanzania: a cross sectional study

    Article • BMC Health Services Research, March 2013, Springer Science + Business Media

    Dr Frank van Leth

93. 
    Benchmarking to Assess Potential Under-Diagnosis of Smear-Negative and Extrapulmonary Tuberculosis. A Case Study from Mozambique

    Article • The Open Infectious Diseases Journal, February 2013, Bentham Science Publishers

    Dr Frank van Leth

94. 
    Are routine tuberculosis programme data suitable to report on antiretroviral therapy use of HIV-infected tuberculosis patients?

    Article • BMC Research Notes, January 2013, Springer Science + Business Media

    Dr Frank van Leth

95. 
    Comparison of direct versus concentrated smear microscopy in detection of pulmonary tuberculosis

    Article • BMC Research Notes, January 2013, Springer Science + Business Media

    Dr Frank van Leth

96. 
    Risk of tuberculosis after antiretroviral treatment initiation: a comparison between efavirenz and nevirapine using inverse probability weighting

    Article • Antiviral Therapy, January 2013, International Medical Press

    Dr Frank van Leth

97. 
    Adherence to Tuberculosis Therapy among Patients Receiving Home-Based Directly Observed Treatment: Evidence from the United Republic of Tanzania

    Article • PLOS One, December 2012, PLOS

    Dr Frank van Leth

98. 
    Adherence by Dutch Public Health Nurses to the National Guidelines for Tuberculosis Contact Investigation

    Article • PLOS One, November 2012, PLOS

    Dr Frank van Leth

99. 
    Unrecognised tuberculosis at antiretroviral therapy initiation is associated with lower CD4+ T cell recovery

    Article • Tropical Medicine & International Health, November 2012, Wiley

    Dr Frank van Leth

100. 
     Socio Economic Position in TB Prevalence and Access to Services: Results from a Population Prevalence Survey and a Facility-Based Survey in Bangladesh

     Article • PLOS One, September 2012, PLOS

     Dr Frank van Leth

101. 
     Implementation and effect of intensified case finding on diagnosis of tuberculosis in a large urban HIV clinic in Uganda: a retrospective cohort study.

     Article • BMC Public Health, August 2012, Springer Science + Business Media

     Dr Frank van Leth

102. 
     The effect of tuberculosis and antiretroviral treatment on CD4+ cell count response in HIV-positive tuberculosis patients in Mozambique

     Article • BMC Public Health, August 2012, Springer Science + Business Media

     Dr Frank van Leth

103. 
     Comment on: Predictors of immune recovery and the association with late mortality while on antiretroviral treatment in Cambodia

     Article • Transactions of the Royal Society of Tropical Medicine and Hygiene, May 2012, Oxford University Press (OUP)

     Dr Frank van Leth

104. 
     Role of the QuantiFERON®-TB Gold In-Tube assay in screening new immigrants for tuberculosis infection

     Article • European Respiratory Journal, April 2012, European Respiratory Society (ERS)

     Dr Frank van Leth

105. 
     Multidrug Resistance Among New Tuberculosis Cases

     Article • Epidemiology, March 2012, Wolters Kluwer Health

     Dr Frank van Leth

106. 
     Comparison of Macroscopic and Microscopic Assessment of Specimens Collected for the Diagnosis of Tuberculosis

     Article • The Open Infectious Diseases Journal, February 2012, Bentham Science Publishers

     Dr Frank van Leth

107. 
     Earlier initiation of antiretroviral therapy, increased tuberculosis case finding and reduced mortality in a setting of improved HIV care: a retrospective cohort study

     Article • HIV Medicine, February 2012, Wiley

     Dr Frank van Leth

108. 
     Contact tracing in low-incidence tuberculosis settings

     Article • The International Journal of Tuberculosis and Lung Disease, December 2011, International Union Against Tuberculosis and Lung Disease

     Dr Frank van Leth

109. 
     Coverage and yield of tuberculosis contact investigations in the Netherlands

     Article • The International Journal of Tuberculosis and Lung Disease, December 2011, International Union Against Tuberculosis and Lung Disease

     Dr Frank van Leth

110. 
     Incidence and Predictors of Mortality and the Effect of Tuberculosis Immune Reconstitution Inflammatory Syndrome in a Cohort of TB/HIV Patients Commencing Antiretroviral Therapy

     Article • JAIDS Journal of Acquired Immune Deficiency Syndromes, September 2011, Wolters Kluwer Health

     Dr Frank van Leth, Prof Robert Colebunders

111. 
     Prevalence of smear-positive tuberculosis in persons aged ⩾15 years in Bangladesh: results from a national survey, 2007–2009

     Article • Epidemiology and Infection, August 2011, Cambridge University Press

     Dr Frank van Leth

112. 
     Highlights of a Symposium, Malaria: Where are we Today, Where are we Going?

     Article • The Open Infectious Diseases Journal, July 2011, Bentham Science Publishers

     Dr Frank van Leth

113. 
     Evaluation of the Genotype® MTBDRplus assay as a tool for drug resistance surveys

     Article • The International Journal of Tuberculosis and Lung Disease, July 2011, International Union Against Tuberculosis and Lung Disease

     Dr Frank van Leth

114. 
     Health-seeking norms for tuberculosis symptoms in southern Angola: implications for behaviour change communications

     Article • The International Journal of Tuberculosis and Lung Disease, July 2011, International Union Against Tuberculosis and Lung Disease

     Dr Frank van Leth

115. 
     Measuring socio-economic data in tuberculosis prevalence surveys

     Article • The International Journal of Tuberculosis and Lung Disease, June 2011, International Union Against Tuberculosis and Lung Disease

     Dr Frank van Leth

116. 
     Missed opportunities in tuberculosis control in The Netherlands due to prioritization of contact investigations

     Article • European Journal of Public Health, March 2011, Oxford University Press (OUP)

     Dr Frank van Leth

117. 
     Patient-centred tuberculosis treatment delivery under programmatic conditions in Tanzania: a cohort study

     Article • BMC Medicine, December 2009, Springer Science + Business Media

     Dr Frank van Leth

118. 
     Malnutrition: More that the eye can see

     Article • East African Medical Journal, October 2009, African Journals Online (AJOL)

     Dr Frank van Leth

119. 
     Projection of the number of patients with tuberculosis in the Netherlands in 2030

     Article • European Journal of Public Health, April 2009, Oxford University Press (OUP)

     Dr Frank van Leth

120. 
     Implementation of a national anti-tuberculosis drug resistance survey in Tanzania

     Article • BMC Public Health, December 2008, Springer Science + Business Media

     Dr Frank van Leth

121. 
     Risk Factors for Smear Negative And Culture Positive Results Among Pulmonary Tuberculosis Patients in Mwanza, Tanzania

     Article • The Open Tropical Medicine Journal, October 2008, Bentham Science Publishers

     Dr Frank van Leth

122. 
     HIV-induced immunodeficiency and mortality from AIDS-defining and non-AIDS-defining malignancies

     Article • AIDS, October 2008, Wolters Kluwer Health

     Dr. Vicente Soriano, Dr Frank van Leth

123. 
     Determination of Clinically Relevant Cutoffs for HIV-1 Phenotypic Resistance Estimates Through a Combined Analysis of Clinical Trial and Cohort Data

     Article • JAIDS Journal of Acquired Immune Deficiency Syndromes, May 2008, Wolters Kluwer Health

     Dr Frank van Leth

124. 
     Measuring tuberculosis burden, trends, and the impact of control programmes

     Article • The Lancet Infectious Diseases, April 2008, Elsevier

     Dr Frank van Leth

125. 
     Prevalence of tuberculous infection and incidence of tuberculosis; a re-assessment of the Styblo rule

     Article • Bulletin of the World Health Organization, January 2008, WHO Press

     Dr Frank van Leth

126. 
     Importance of Baseline Prognostic Factors With Increasing Time Since Initiation of Highly Active Antiretroviral Therapy

     Article • JAIDS Journal of Acquired Immune Deficiency Syndromes, December 2007, Wolters Kluwer Health

     Dr Maria Rosaria Capobianchi, Dr. Vicente Soriano, Dr Frank van Leth

127. 
     Methodological standards in non-inferiority AIDS trials: moving from adherence to compliance: Response

     Article • BMC Medical Research Methodology, March 2007, Springer Science + Business Media

     Dr Frank van Leth

128. 
     Epstein‐Barr Virus Infects B and Non‐B Lymphocytes in HIV‐1–Infected Children and Adolescents

     Article • The Journal of Infectious Diseases, November 2006, Oxford University Press (OUP)

     Dr Frank van Leth

129. 
     Plasma lipid concentrations after 1.5 years of exposure to nevirapine or efavirenz together with stavudine and lamivudine

     Article • HIV Medicine, September 2006, Wiley

     Dr Frank van Leth

130. 
     Liver-Related Deaths in Persons Infected With the Human Immunodeficiency Virus

     Article • Archives of Internal Medicine, August 2006, American Medical Association (AMA)

     Dr. Vicente Soriano, Dr Frank van Leth

131. 
     Pharmacokinetic Parameters of Nevirapine and Efavirenz in Relation to Antiretroviral Efficacy

     Article • AIDS Research and Human Retroviruses, March 2006, Mary Ann Liebert Inc

     Dr Frank van Leth

132. 
     Long-term Experience With Combination Antiretroviral Therapy That Contains Nelfinavir for up to 7 Years in a Pediatric Cohort

     Article • PEDIATRICS, March 2006, American Academy of Pediatrics (AAP)

     Dr Frank van Leth

133. 
     Incidence of Tuberculosis among HIV-Infected Patients Receiving Highly Active Antiretroviral Therapy in Europe and North America

     Article • Clinical Infectious Diseases, December 2005, Oxford University Press (OUP)

     Dr. Vicente Soriano, Dr Frank van Leth

134. 
     Pharmacokinetics of Nevirapine: Once-Daily Versus Twice-Daily Dosing in the 2NN Study

     Article • HIV Clinical Trials, October 2005, Taylor & Francis

     Dr Frank van Leth

135. 
     Protease inhibitors and non-nucleoside reverse transcriptase inhibitors have a comparable effect on the CD4 cell change after switching to tenofovir-based regimens

     Article • AIDS, October 2005, Wolters Kluwer Health

     Dr Frank van Leth

136. 
     Cytomegalovirus rather than HIV triggers the outgrowth of effector CD8+CD45RA+CD27− T cells in HIV-1-infected children

     Article • AIDS, July 2005, Wolters Kluwer Health

     Dr Frank van Leth

137. 
     The effect of baseline CD4 cell count and HIV-1 viral load on the efficacy and safety of nevirapine or efavirenz-based first-line HAART

     Article • AIDS, March 2005, Wolters Kluwer Health

     Dr Frank van Leth

138. 
     Nevirapine and Efavirenz Elicit Different Changes in Lipid Profiles in Antiretroviral- Therapy-Naive Patients Infected with HIV-1

     Article • PLoS Medicine, October 2004, PLOS

     Dr Frank van Leth

139. 
     Highly active antiretroviral therapy with or without mycophenolate mofetil in treatment-naive HIV-1 patients

     Article • AIDS, September 2004, Wolters Kluwer Health

     Dr Frank van Leth

140. 
     Comparison of first-line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: a randomised open-label trial, the 2NN Study

     Article • The Lancet, April 2004, Elsevier

     Dr Frank van Leth

141. 
     Lipid Profiles in HIV‐Infected Patients Receiving Combination Antiretroviral Therapy: Are Different Antiretroviral Drugs Associated with Different Lipid Profiles?

     Article • The Journal of Infectious Diseases, March 2004, Oxford University Press (OUP)

     Dr Frank van Leth

142. 
     Differential CD4 T-cell response in HIV-1-infected patients using protease inhibitor-based or nevirapine-based highly active antiretroviral therapy

     Article • HIV Medicine, March 2004, Wiley

     Dr Frank van Leth

143. 
     Disseminating Health Care Innovation

     Article • JAMA, September 2003, American Medical Association (AMA)

     Dr Frank van Leth

144. 
     A randomized trial to study first-line combination therapy with or without a protease inhibitor in HIV-1-infected patients

     Article • AIDS, May 2003, Wolters Kluwer Health

     Dr Frank van Leth

145. 
     Identifying malnourished children may not be easy

     Article • BMJ, April 2003, BMJ

     Dr Frank van Leth

146. 
     Highly Active Antiretroviral Therapy-Induced Lipodystrophy Has Minor Effects on Human Immunodeficiency Virus-Induced Changes in Lipolysis, but Normalizes Resting Energy Expenditure

     Article • The Journal of Clinical Endocrinology & Metabolism, November 2002, Endocrine Society

     Dr Frank van Leth

147. 
     Nevirapine-containing antiretroviral therapy in HIV-1 infected patients results in an anti-atherogenic lipid profile

     Article • AIDS, December 2001, Wolters Kluwer Health

     Dr Frank van Leth